![](/images/graphics-bg.png)
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
المؤلفون المشاركون
Kovac, Viljem
Štrbac, Danijela
Goričar, Katja
Dolžan, Vita
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-05-02
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
Malignant mesothelioma (MM) is a rare, but fatal disease with few treatment options.
The diagnosis and treatment response are challenging in MM.
Therefore, the search for novel diagnostic and prognostic biomarkers is ongoing.
The aim of our study was to investigate matrix metalloproteinase 9 (MMP9) as a potential serum biomarker of treatment response and survival in MM.
We also investigated the influence of genetic polymorphisms on MMP9 serum levels.
Methods.
We included 110 patients with MM that have been previously genotyped for common MMP9 polymorphisms.
Serum samples were collected before treatment, at the end of chemotherapy, and at the time of progression.
MMP9 serum levels were measured using enzyme-linked immunosorbent assay kits.
The role of serum MMP9 and MMP9 polymorphisms in treatment response was determined using the nonparametric tests and logistic or Cox regression.
Results.
Median serum MMP9 was 706.7 (499.6-1224.9) ng/ml before treatment, 440.5 (255.9-685.2) ng/ml after chemotherapy, and 502.8 (307.2-851.4) ng/ml at disease progression.
After chemotherapy, 87 (79.8%) patients had lower serum MMP9, with the median change of -286.3 (-607.3 to -70.2) ng/ml (P<0.001).
At disease progression, 47 (65.3%) patients had lower serum MMP9 compared to pretreatment values, with the median change of -163.7 (-466.6 to 108.6) ng/ml (P=0.001).
Patients with higher performance status had higher serum MMP9 before treatment (P=0.010).
Among investigated polymorphisms, only rs17576 was associated with serum MMP9 levels before treatment (P=0.041).
Conclusion.
Median serum MMP9 levels differed significantly before and after treatment of MM, but failed to reach significance as a standalone biomarker.
The contribution of MMP9 serum levels and MMP9 polymorphisms to a composite diagnostic and prognostic biomarker should be further tested.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Štrbac, Danijela& Goričar, Katja& Dolžan, Vita& Kovac, Viljem. 2019. Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma. Disease Markers،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1146852
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Štrbac, Danijela…[et al.]. Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma. Disease Markers No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1146852
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Štrbac, Danijela& Goričar, Katja& Dolžan, Vita& Kovac, Viljem. Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1146852
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1146852
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)